We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Due to positive results, a phase 3 trial for Sanofi’s and Regeneron’s Libtayo (cemiplimab) monotherapy for cervical cancer will be stopped early. Read More
Gilead Sciences and Merck, rivals in the HIV space, have agreed to jointly develop two long-acting experimental HIV treatments into a two-drug regimen to be taken every few months. Read More
Additional phase 2 trial data for Eli Lilly’s Alzheimer’s drug candidate donanemab showed that the monoclonal antibody helped to significantly slow cognitive and functional decline and clear amyloid plaques in patients. Read More
The FDA has launched a new online dashboard for adverse event reporting of COVID-19 products that have received Emergency Use Authorizations (EUAs). Read More
HHS announced that it will restrict distribution of Eli Lilly’s COVID-19 antibody therapy, bamlanivimab, in three states because of concerns about its effectiveness against a variant strain of the virus first identified in California. Read More
Moderna announced that it has dosed the first participants in its phase 1 trial of mRNA-1283, its “next generation” COVID-19 vaccine candidate that’s being developed to have more relaxed temperature requirements for easier distribution and administration. Read More
France, Italy and Germany have become the latest European countries to halt inoculations with AstraZeneca’s COVID-19 vaccine after 37 cases of blood clots were reported, joining an increasing number of other member states in temporarily putting them on pause as a safety review is conducted. Read More
A study by researchers at the University of Utah and other universities found that payments for neurology drugs under Medicare Part D saw a substantial hike over five years despite only a small bump in the number of claims. Read More